Drug class

Pseudomembranous Colitis Agents

"Pseudomembranous colitis agents" is an indication-based clinical grouping rather than a distinct pharmacological drug class. Read more about Pseudomembranous Colitis Agents

55 drugs in this class 45 manufacturers

Advertisement

Drugs in Pseudomembranous Colitis Agents

Showing 37–45 of 55 drugs

METRONIDAZOLE

ACNE ANTIBIOTICS · ACUTE INTESTINAL AMEBIASIS DUE TO ENTAMOEBA HISTOLYTICA ·+54
BRYANT RANCH PR

VANCOMYCIN HCL

PSEUDOMEMBRANOUS COLITIS AGENTS · STAPHYLOCOCCAL ENTEROCOLITIS ·+1
BRYANT RANCH PR

METRONIDAZOLE

NITROIMIDAZOLE ANTIBIOTICS · ACUTE INTESTINAL AMEBIASIS DUE TO ENTAMOEBA HISTOLYTICA ·+54
NUCARE PHARMACE

VANCOMYCIN HCL

PSEUDOMEMBRANOUS COLITIS AGENTS · STAPHYLOCOCCAL ENTEROCOLITIS ·+1
ASCEND LABORATO

METRONIDAZOLE

NITROIMIDAZOLE ANTIBIOTICS · ACUTE INTESTINAL AMEBIASIS DUE TO ENTAMOEBA HISTOLYTICA ·+54
DENTON PHARMA I

METRONIDAZOLE

NITROIMIDAZOLE ANTIBIOTICS · ACUTE INTESTINAL AMEBIASIS DUE TO ENTAMOEBA HISTOLYTICA ·+54
PD-RX PHARM

METRONIDAZOLE

NITROIMIDAZOLE ANTIBIOTICS · ACUTE INTESTINAL AMEBIASIS DUE TO ENTAMOEBA HISTOLYTICA ·+54
Avet Pharmaceuticals

VANCOMYCIN HCL

PSEUDOMEMBRANOUS COLITIS AGENTS · STAPHYLOCOCCAL ENTEROCOLITIS ·+1
Avet Pharmaceuticals

LIKMEZ (metronidazole)

NITROIMIDAZOLE ANTIBIOTICS · ACUTE INTESTINAL AMEBIASIS DUE TO ENTAMOEBA HISTOLYTICA ·+54
SAPTALIS PHARMA
Filter & compare in the drug finder → Opens the drug finder with Pseudomembranous Colitis Agents preselected. Add indication or manufacturer filters there.

About Pseudomembranous Colitis Agents.

"Pseudomembranous colitis agents" is an indication-based clinical grouping rather than a distinct pharmacological drug class.

It refers to antimicrobial medications used to eradicate toxin-producing *Clostridioides difficile*, the primary pathogen responsible for severe antibiotic-associated mucosal inflammation and pseudomembrane formation in the large intestine.

These therapies—predominantly orally administered narrow- or targeted-spectrum agents such as oral vancomycin and fidaxomicin, as well as metronidazole—work by inhibiting bacterial cell-wall synthesis, RNA polymerase transcription, or DNA replication locally within the gastrointestinal tract.

Consequently, their primary therapeutic application is the treatment and clinical resolution of acute or recurrent *C.

difficile*–associated diarrhea and pseudomembranous colitis.